Altus Formulation Inc.: Cadila Pharmaceuticals and Altus Formulation Announce Successful Clinical Studies with TramaFlex Breakable Extended-Release Tablets
tm Modified Release Technology Platform:
New Safer to Use Value Added Tablets
AHMEDABAD, INDIA and LAVAL, QC / ACCESSWIRE / January 27, 2021 / Cadila Pharmaceuticals Limited (
Cadila ) and
Altus ) today announced the successful completion of human clinical studies with TramaFlex
TM breakable extended-release (ER) tablets, a novel value-added once-daily formulation of tramadol hydrochloride for the improved treatment of patients with moderate to moderately severe pain.
Developed by Altus using proprietary AmyloFlex
TM technology, human bio-equivalence studies conducted by Cadila demonstrated TramaFlex ER tablets are bio-equivalent to 24hr ER products available commercially in North America, Europe, and Asia. Unlike marketed brands that can rapidly release their entire contents if damaged, with potentially life-threatenin
Cadila Pharmaceuticals and Altus Formulation Announce Successful Clinical Studies with TramaFlex Breakable Extended-Release Tablets theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.